On Nov.13, BioXcel Therapeutics Reported Q3 Adjusted EPS $(1.58) Misses $(1.31) Estimate, Sales $341.00K Miss $670.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics (NASDAQ:BTAI) reported a Q3 adjusted EPS of $(1.58), missing the $(1.31) estimate, and sales of $341.00K, missing the $670.00K estimate. The EPS miss represents a 20.61% deviation from expectations and a 6.04% decrease from the previous year. Sales increased by 148.91% compared to the same period last year, but still fell short of expectations by 49.10%.
November 14, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics reported weaker than expected Q3 earnings and revenue, missing EPS estimates by 20.61% and sales forecasts by 49.10%.
The significant miss in both earnings per share and sales compared to analyst estimates is likely to negatively impact investor sentiment and the stock price in the short term. The historical performance of stocks following an earnings miss suggests a potential decline in share price as the market adjusts to the new information.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100